View Financial HealthJoint 配当と自社株買い配当金 基準チェック /06Joint配当金を支払った記録がありません。主要情報n/a配当利回り7.7%バイバック利回り総株主利回り7.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesThe Joint Corp. to Report Q1, 2026 Results on May 07, 2026Apr 23The Joint Corp. Announces Appointment of Michelle Reap as Director of Franchise DevelopmentApr 14The Joint Corp., Annual General Meeting, May 20, 2026Apr 08Full year 2025 earnings: EPS and revenues exceed analyst expectations Mar 15New major risk - Revenue and earnings growth Mar 13The Joint Corp. Provides Earnings Guidance for the Year 2026Mar 13The Joint Corp. to Report Q4, 2025 Results on Mar 12, 2026Feb 26Estimating The Fair Value Of The Joint Corp. (NASDAQ:JYNT)Feb 11The Joint Corp. Announces Executive ChangesJan 06Third quarter 2025 earnings: EPS exceeds analyst expectations Nov 12the Joint Corp. Revises Earnings Guidance for the Full Year 2025Nov 07The Joint Corp. to Report Q3, 2025 Results on Nov 06, 2025Oct 23The Joint Corp. Announces Executive ChangesOct 01The Joint Corp. announced delayed 10-Q filingAug 13Second quarter 2025 earnings: EPS exceeds analyst expectations Aug 10Price target decreased by 9.2% to US$14.88 Aug 08The Joint Corp. Revises Earnings Guidance for the Full Year 2025Aug 08+ 1 more updateThe Joint Corp. to Report Q2, 2025 Results on Aug 07, 2025Jul 24Joint Ventures, LLC completed the acquisition of 31 corporate owned and managed clinics in Arizona and New Mexico from The Joint Corp. (NasdaqCM:JYNT) for $8.3 million.Jul 08the Joint Corp. Announces CFO Changes, Effective June 10, 2025Jun 11The Joint Corp. Appoints Sandi Karrmann as DirectorJun 04First quarter 2025 earnings: EPS exceeds analyst expectations May 10The Joint Corp. Reiterates Earnings Guidance for the Full Year 2025May 09The Joint Corp. Announces Executive AppointmentsMay 06The Joint Corp. Has Shown Good Momentum For Future Returns (Rating Upgrade) Apr 29The Joint Corp. to Report Q1, 2025 Results on May 08, 2025Apr 24The Joint Corp., Annual General Meeting, May 21, 2025Apr 10There's Reason For Concern Over The Joint Corp.'s (NASDAQ:JYNT) PriceMar 20Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 14The Joint Corp. Provides Earnings Guidance for the Full Year 2025Mar 14The Joint Corp. Appoints Craig Sherwood as Senior Vice President of DevelopmentMar 11The Joint Corp.'s (NASDAQ:JYNT) Intrinsic Value Is Potentially 59% Above Its Share PriceJan 22The Joint Corp. to Report Q4, 2024 Results on Mar 13, 2025Jan 16The Joint Corp. Adjusts System-Wide Sales Guidance for 2024Nov 09Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08The Joint Corp. Updates Earnings Guidance for the Year 2024Nov 08The Joint Corp. to Report Q3, 2024 Results on Nov 07, 2024Oct 24The Joint Corp. Announces Chief Executive Officer ChangesOct 15+ 1 more updateThe Joint Corp.'s (NASDAQ:JYNT) Price Is Out Of Tune With RevenuesSep 14Now 23% undervalued after recent price drop Aug 11Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09The Joint Corp. (NASDAQ:JYNT) Shares Could Be 22% Above Their Intrinsic Value EstimateAug 05The Joint Corp. to Report Q2, 2024 Results on Aug 08, 2024Jul 25Investors Could Be Concerned With Joint's (NASDAQ:JYNT) Returns On CapitalJul 17New minor risk - Shareholder dilution May 07Price target increased by 9.7% to US$13.38 May 05Optimistic Investors Push The Joint Corp. (NASDAQ:JYNT) Shares Up 26% But Growth Is LackingMay 04First quarter 2024 earnings: EPS exceeds analyst expectations May 04The Joint Corp. Reiterates Sales Guidance for the Year 2024May 03The Joint Corp., Annual General Meeting, May 22, 2024Apr 21The Joint Corp. to Report Q1, 2024 Results on May 02, 2024Apr 20The Joint Corp.'s (NASDAQ:JYNT) Share Price Not Quite Adding UpMar 10New minor risk - Share price stability Mar 09Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 08The Joint Corp. Provides Sales Guidance for the Year 2024Mar 08Investor sentiment improves as stock rises 15% Feb 12Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)Feb 12The Joint Corp. to Report Second Half, 2023 Results on Mar 07, 2024Jan 12Consensus EPS estimates fall by 42% Nov 20Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15Insufficient new directors Nov 15The Joint Corp. Reiterates Revenue Guidance for the Year 2023Nov 11The Joint Corp. Appoints Jeff Gramm to the Board of Directors, Effective January 2, 2024Nov 09The Joint Corp. to Report Q3, 2023 Results on Nov 09, 2023Oct 27The Joint Corp. Revises Earnings Guidance for the Year 2023Sep 14The Joint Announces Receipt of Delinquency Notification Letter from NasdaqAug 26The Joint Corp. announced delayed 10-Q filingAug 17The Joint Corp. Appoints Lori Abou Habib as New Chief Marketing OfficerAug 15Price target decreased by 8.5% to US$27.17 Aug 11The Joint Corp. to Report Q2, 2023 Results on Aug 10, 2023Jul 14Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To ContinueJun 17The Joint Corp. Provides Earnings Guidance for the Year 2023May 06First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 06Price target increased by 11% to US$29.70 Apr 08Consensus EPS estimates fall by 44%, revenue upgraded Mar 17Full year 2022 earnings: EPS misses analyst expectations Mar 10The Joint Corp. to Report Q4, 2022 Results on Mar 09, 2023Jan 13The Joint Corp. Appoints Krischelle Tennessen as Chief Human Resources OfficerJan 06Joint's (NASDAQ:JYNT) Returns On Capital Are Heading HigherJan 04The Joint Corp. (NasdaqCM:JYNT)acquired Six franchised clinics in Northern California.Jan 04Insufficient new directors Nov 16Consensus forecasts updated Nov 11Price target decreased to US$28.08 Nov 06Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.14 in 3Q 2021) Nov 05Price target decreased to US$30.08 Nov 04The Joint Corp. Provides Earnings Guidance for the Fiscal Year 2022Nov 04Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?Oct 27The Joint Corp. to Report Q3, 2022 Results on Nov 03, 2022Oct 21The Joint Corp. Can Relieve You From High Inflation Pain Oct 17The Joint Corp. Reaffirms Revenue Guidance for 2022Aug 06決済の安定と成長配当データの取得安定した配当: JYNTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: JYNTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Joint 配当利回り対市場JYNT 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (JYNT)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare)2.1%アナリスト予想 (JYNT) (最長3年)n/a注目すべき配当: JYNTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: JYNTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: JYNTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: JYNTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/04/30 17:01終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Joint Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Jeffrey Van SinderenB. Riley Securities, Inc.Jeremy HamblinCraig-Hallum Capital Group LLCLinda Bolton-WeiserD.A. Davidson & Co.2 その他のアナリストを表示
Joint Ventures, LLC completed the acquisition of 31 corporate owned and managed clinics in Arizona and New Mexico from The Joint Corp. (NasdaqCM:JYNT) for $8.3 million.Jul 08